Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging and response in soft tissue sarcomas.

Scott M Schuetze1

  • 1Division of Hematology/Oncology, Box 0848, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0848, USA. scotschu@med.umich.edu

Hematology/Oncology Clinics of North America
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.

Lancet (London, England)·2024
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Functional imaging, like positron emission tomography (PET), offers better insights into soft tissue sarcoma viability and treatment response than standard scans. PET

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Conventional CT and MRI scans excel at anatomical detail for soft tissue sarcomas.
  • These methods are limited in assessing tumor viability and response to therapy.
  • Functional imaging offers a potential solution for evaluating biological properties within sarcomas.

Purpose of the Study:

  • To explore the utility of functional imaging in assessing soft tissue sarcoma response to treatment.
  • To highlight positron emission tomography (PET) as a quantitative functional imaging modality.
  • To discuss the correlation between imaging biomarkers and clinical outcomes.

Main Methods:

  • Review of various functional imaging approaches for soft tissue sarcomas.
  • Focus on positron emission tomography (PET) for quantitative assessment.

Related Experiment Videos

  • Analysis of tumor glucose uptake as a key biomarker.

    • Main Results:

    • PET imaging demonstrates quantitative measurement of biological processes in sarcomas.
    • Decreased tumor glucose uptake via PET correlates with improved outcomes.
    • This has been observed in high-grade extremity soft tissue sarcomas and gastrointestinal stromal tumors.

    Conclusions:

    • Functional imaging, particularly PET, shows promise for evaluating soft tissue sarcoma treatment response.
    • PET's ability to measure tumor viability and glucose metabolism is clinically relevant.
    • Further research into functional imaging for sarcomas is warranted to optimize patient care.